Projects per year
Abstract
PURPOSE: We examined the association between use of beta-blockers and survival in pancreatic cancer patients after curative-intent surgery.
METHODS: Using Danish healthcare registries, we conducted a population-based cohort study of all patients undergoing curative-intent surgery for pancreatic cancer in Denmark 1997-2021. We defined beta-blocker use according to exposure before surgery as current (≤90 days), recent (91-365 days), or former (366-730 days) use, requiring at least one filled prescription. Patients were followed from the date of surgery for up to 5 years. We used Cox regression to compute hazard ratios (HRs) of deaths with 95% confidence intervals (CIs), adjusting for age, sex, year of diagnosis, cardiovascular disease, diabetes, liver disease, alcohol, and smoking. We also conducted an active comparator analysis, where we used angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers as comparators instead of nonusers.
RESULTS: We included 2592 patients, of which 16.7% were beta-blocker users. Median survival for the entire population was 24.4 months. Beta-blocker use was associated with increased mortality (adjusted HR: 1.18; 95% CI: 1.04-1.34). This was evident in current (adjusted HR: 1.19; 95% CI: 1.02-1.38) and recent (adjusted HR: 1.29; 95% CI: 1.04-1.59) but not former (adjusted HR: 0.91; 95% CI: 0.64-1.43) users. In the active comparator analysis, the association between beta-blocker exposure and mortality attenuated slightly (adjusted HR: 1.12; 95% CI: 0.93-1.35).
CONCLUSIONS: We observed an association between beta-blocker use and increased mortality in patients operated for pancreatic cancer. Findings are likely explained by confounding by indication.
Original language | English |
---|---|
Article number | e5726 |
Journal | Pharmacoepidemiology and Drug Safety |
Volume | 33 |
Issue | 1 |
Number of pages | 10 |
ISSN | 1053-8569 |
DOIs | |
Publication status | Published - Jan 2024 |
Keywords
- beta-blockers
- epidemiology
- pancreatic cancer
- pharmacoepidemiology
- prognosis
- survival
- Adrenergic beta-Antagonists/adverse effects
- Angiotensin-Converting Enzyme Inhibitors
- Humans
- Proportional Hazards Models
- Pancreatic Neoplasms/epidemiology
- Cohort Studies
Fingerprint
Dive into the research topics of 'Beta-blocker use and survival after pancreatic cancer surgery: A nationwide population-based cohort study'. Together they form a unique fingerprint.Projects
- 1 Finished
-
Pancreatitis and Pancreatic Cancer Risk and Prognosis
Kirkegård, J. (PI), Mortensen, F. V. (Collaborator) & Cronin Fenton, D. (Collaborator)
01/05/2016 → 31/12/2023
Project: Research
Press/Media
-
Kan kendte lægemidler beskytte mod kræft i bugspytkirtlen?
29/07/2015
1 item of Media coverage
Press/Media: Press / Media
-